Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive‐Stage Small Cell Lung Cancer

BACKGROUND: Small cell lung cancer (SCLC) represents approximately 15% of lung cancers, and approximately 70% are diagnosed as extensive‐stage SCLC (ES‐SCLC). Although ES‐SCLC is highly responsive to chemotherapy, patients typically progress rapidly, and there is an urgent need for new therapies. Im...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Oncologist
Main Authors: Melosky, Barbara, Cheema, Parneet K., Brade, Anthony, McLeod, Deanna, Liu, Geoffrey, Price, Paul Wheatley, Jao, Kevin, Schellenberg, Devin D., Juergens, Rosalyn, Leighl, Natasha, Chu, Quincy
Format: Artigo
Jezik:Inglês
Izdano: John Wiley & Sons, Inc. 2020
Teme:
Lung Cancer
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7648366/
https://ncbi.nlm.nih.gov/pubmed/32860288
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0193
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki